参考文献/References:
[1] Hesarghatta Shyamasunder A,Abraham P. Measuring TSH receptor antibody to influence treatment choices in Graves' disease[J].Clin Endocrinol(Oxf),2017,86(5):652-657.DOI:10.1111/cen.13327.
[2] Ross DS,Burch HB,Cooper DS,et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis[J].Thyroid,2016,26(10):1343-1421.DOI:10.1089/thy.2016.0229.
[3] Kotwal A,Stan M. Thyrotropin receptor antibodies-an overview[J].Ophthalmic Plast Reconstr Surg,2018,34(4S Suppl 1):S20-S27.DOI:10.1097/iop.0000000000001052.
[4] Smith TJ,Hegedüs L. Graves' disease[J].N Engl J Med,2016,375(16):1552-1565.DOI:10.1056/NEJMra1510030.
[5] Neumann S,Place RF,Krieger CC,et al. Future prospects for the treatment of Graves' hyperthyroidism and eye disease[J].Horm Metab Res,2015,47(10):789-796.DOI:10.1055/s-0035-1555901.
[6] Sanders J,Jeffreys J,Depraetere H,et al. Thyroid-stimulating monoclonal antibodies[J].Thyroid,2002,12(12):1043-1050.DOI:10.1089/105072502321085135.
[7] Doroudian S,Pedersen IB,Knudsen CS,et al. Comparison of three competitive immunoassays for measurement of TSH receptor antibodies in patients with Graves' disease[J].Scand J Clin Lab Invest,2017,77(7):535-540.DOI:10.1080/00365513.2017.1354257.
[8] Tozzoli R,Bagnasco M,Giavarina D,et al. TSH receptor autoantibody immunoassay in patients with Graves' disease:improvement of diagnostic accuracy over different generations of methods. Systematic review and meta-analysis[J].Autoimmun Rev,2012,12(2):107-113.DOI:10.1016/j.autrev.2012.07.003.
[9] Araki N,Iida M,Amino N,et al. Rapid bioassay for detection of thyroid-stimulating antibodies using cyclic adenosine monophosphate-gated calcium channel and aequorin[J].Eur Thyroid J,2015,4(1):14-19.DOI:10.1159/000371740.
[10] Frank CU,Braeth S,Dietrich JW,et al. Bridge technology with TSH receptor Chimera for sensitive direct detection of TSH receptor antibodies causing Graves' disease:analytical and clinical evaluation[J].Horm Metab Res,2015,47(12):880-888.DOI:10.1055/s-0035-1554662.
[11] Cheng XQ,Chai XF,Ma CC,et al. Clinical diagnostic performance of a fully automated TSI immunoassay vs. that of an automated antiTSHR immunoassay for Graves' disease:a Chinese multicenter study[J].Endocrine,2020.DOI:10.1007/s12020-020-02386-2.
[12] Bell L,Hunter AL,Kyriacou A,et al. Clinical diagnosis of Graves' or non-Graves' hyperthyroidism compared to TSH receptor antibody test[J].Endocr Connect,2018,7(4):504-510.DOI:10.1530/ec-18-0082.
[13] Mckee A,Peyerl F. TSI assay utilization:impact on costs of Graves' hyperthyroidism diagnosis[J].Am J Manag Care,2012,18(1):e1-14.
[14] Kim JJ,Jeong SH,Kim B,et al. Analytical and clinical performance of newly developed immunoassay for detecting thyroid-stimulating immunoglobulin,the Immulite TSI assay[J].Scand J Clin Lab Invest,2019,79(6):443-448.DOI:10.1080/00365513.2019.1658216.
[15] Allelein S,Ehlers M,Goretzki S,et al. Clinical evaluation of the first automated assay for the detection of stimulating TSH receptor autoantibodies[J].Horm Metab Res,2016,48(12):795-801.DOI:10.1055/s-0042-121012.
[16] Laurberg P,Wallin G,Tallstedt L,et al. TSH-receptor autoimmunity in Graves' disease after therapy with anti-thyroid drugs,surgery,or radioiodine:a 5-year prospective randomized study[J].Eur J Endocrinol,2008,158(1):69-75.DOI:10.1530/eje-07-0450.
[17] Carella C,Mazziotti G,Sorvillo F,et al. Serum thyrotropin receptor antibodies concentrations in patients with Graves' disease before,at the end of methimazole treatment,and after drug withdrawal:evidence that the activity of thyrotropin receptor antibody and/or thyroid response modify during the observation period[J].Thyroid,2006,16(3):295-302.DOI:10.1089/thy.2006.16.295.
[18] Kahaly G J,Diana T,Kanitz M,et al. Prospective trial of functional thyrotropin receptor antibodies in Grave's disease[J].J Clin Endocrinol Metab,2020,105(4):e1006-1014.DOI:10.1210/clinem/dgz292.
[19] Hwang S,Shin DY,Song MK,et al. High cut-off value of a chimeric TSH receptor(Mc4)-based bioassay may improve prediction of relapse in Graves' disease for 12 months[J].Endocrine,2015,48(1):89-95.DOI:10.1007/s12020-014-0325-8.
[20] Rosenberg Bezalel S,Elbirt D,Leiba H,et al. Graves' opthalmopathy[J].Isr Med Assoc J,2017,19(3):188-192.
[21] Seo S,Sánchez Robledo M. Usefulness of TSH receptor antibodies as biomarkers for Graves' ophthalmopathy:a systematic review[J].J Endocrinol Invest,2018,41(12):1457-1468.DOI:10.1007/s40618-018-0945-6.
[22] Roos JCP,Paulpandian V,Murthy R. Serial TSH-receptor antibody levels to guide the management of thyroid eye disease:the impact of smoking,immunosuppression,radio-iodine,and thyroidectomy[J].Eye(Lond),2019,33(2):212-217.DOI:10.1038/s41433-018-0242-9.
[23] Woo YJ,Jang SY,Lim TH,et al. Clinical association of thyroid stimulating hormone receptor antibody levels with disease severity in the chronic inactive stage of Graves' orbitopathy[J].Korean J Ophthalmol,2015,29(4):213-219.DOI:10.3341/kjo.2015.29.4.213.
[24] Jang SY,Shin DY,Lee EJ,et al. Correlation between TSH receptor antibody assays and clinical manifestations of Graves' orbitopathy[J].Yonsei Med J,2013,54(4):1033-1039.DOI:10.3349/ymj.2013.54.4.1033.
[25] Li Y,Xu T,Mo Q,et al. Thyrotropin receptor antibody:a novel risk indicator for pregnancy loss[J].Clin Biochem,2019,64:44-48.DOI:10.1016/j.clinbiochem.2018.11.017.
[26] Alexander EK,Pearce EN,Brent GA,et al. 2017 Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and the postpartum[J].Thyroid,2017,27(3):315-389.DOI:10.1089/thy.2016.0457.
[27] Abeillon-Du Payrat J,Chikh K,Bossard N,et al. Predictive value of maternal second-generation thyroid-binding inhibitory immunoglobulin assay for neonatal autoimmune hyperthyroidism[J].Eur J Endocrinol,2014,171(4):451-460.DOI:10.1530/eje-14-0254.
[28] Peleg D,Cada S,Peleg A,et al. The relationship between maternal serum thyroid-stimulating immunoglobulin and fetal and neonatal thyrotoxicosis[J].Obstet Gynecol,2002,99(6):1040-1043.DOI:10.1016/s0029-7844(02)01961-0.
[29] Ide A,Amino N,Nishihara E,et al. Partial prediction of postpartum Graves' thyrotoxicosis by sensitive bioassay for thyroid-stimulating antibody measured in early pregnancy[J].Endocr J,2016,63(10):929-932.DOI:10.1507/endocrj.EJ16-0296.
相似文献/References:
[1]陈宁,朱云娟,陈慧,等.TSHR胞外区中间段在BALB/c小鼠体内的免疫原性研究[J].国际内分泌代谢杂志,2007,(04):267.
[2]贾媛媛,陈莉丽.Th17细胞与Graves病及桥本甲状腺炎[J].国际内分泌代谢杂志,2014,(05):344.[doi:10.3760/cma.j.issn.1673-4157.2014.05.016]
Jia Yuanyuan,Chen Lili.Relationship between Th17 cells and Graves' disease,Hashimoto's thyroiditis[J].International Journal of Endocrinology and Metabolism,2014,(01):344.[doi:10.3760/cma.j.issn.1673-4157.2014.05.016]
[3]房方,卫红艳,王坤玲,等.硒治疗自身免疫性甲状腺疾病的荟萃分析[J].国际内分泌代谢杂志,2016,36(04):247.[doi:10.3760/cma.j.issn.1673-4157.2016.04.09]
Fang Fang,Wei Hongyan,Wang Kunling,et al.A meta-analysis of selenium in the treatment of autoimmune thyroid diseases[J].International Journal of Endocrinology and Metabolism,2016,36(01):247.[doi:10.3760/cma.j.issn.1673-4157.2016.04.09]
[4]郑仁东,刘超.白细胞介素-6与甲状腺疾病[J].国际内分泌代谢杂志,2016,36(05):352.[doi:10.3760/cma.j.issn.1673-4157.2016.05.18]
Zheng Rendong,Liu Chao.Interleukin-6 and thyroid disease[J].International Journal of Endocrinology and Metabolism,2016,36(01):352.[doi:10.3760/cma.j.issn.1673-4157.2016.05.18]
[5]郑慧娟,魏璠,魏军平.自噬与自身免疫性甲状腺疾病[J].国际内分泌代谢杂志,2017,37(01):17.[doi:10.3760/cma.j.issn.1673-4157.2017.01.05]
Zheng Huijuan,Wei Fan,Wei Junping..Autophagy and autoimmune thyroid disease[J].International Journal of Endocrinology and Metabolism,2017,37(01):17.[doi:10.3760/cma.j.issn.1673-4157.2017.01.05]
[6]韩煦,魏军平.促甲状腺激素受体抗体的检测及其在Graves病
诊疗中的价值[J].国际内分泌代谢杂志,2017,37(02):94.[doi:10.3760/cma.j.issn.1673-4157.2017.02.006]
Han Xu,Wei Junping..Thyroid stimulating hormone receptor antibodies assays and its clinical significance in Graves' disease[J].International Journal of Endocrinology and Metabolism,2017,37(01):94.[doi:10.3760/cma.j.issn.1673-4157.2017.02.006]
[7]黄慧 胡欣 徐一娇 刘超.利妥昔单克隆抗体治疗Graves病的作用机制[J].国际内分泌代谢杂志,2018,38(02):121.[doi:10.3760/cma.j.issn.1673-4157.2018.02.013]
Huang Hui,Hu Xin,Xu Yijiao,et al.Mechanism of rituximab in the treatment of Graves' disease[J].International Journal of Endocrinology and Metabolism,2018,38(01):121.[doi:10.3760/cma.j.issn.1673-4157.2018.02.013]
[8]苏亚峰 相萍萍 陈国芳 刘超.碘治疗Graves病的研究进展[J].国际内分泌代谢杂志,2019,39(01):21.[doi:10.3760/cma.j.issn.1673-4157.2019.01.005]
Su Yafeng,Xiang Pingping,Chen Guofang,et al.Research progress of iodine in treating Graves' disease[J].International Journal of Endocrinology and Metabolism,2019,39(01):21.[doi:10.3760/cma.j.issn.1673-4157.2019.01.005]
[9]赫晓晴 单忠艳.肠道菌群与自身免疫性甲状腺疾病[J].国际内分泌代谢杂志,2020,40(03):179.[doi:10.3760/cma.j.issn.1673-4157.2020.03.008]
He Xiaoqing,Shan Zhongyan.Gut microbiota and autoimmune thyroid disease[J].International Journal of Endocrinology and Metabolism,2020,40(01):179.[doi:10.3760/cma.j.issn.1673-4157.2020.03.008]
[10]龙丽 张秀英 纪立农.甲状腺相关眼病治疗新希望——IGF-Ⅰ受体拮抗剂[J].国际内分泌代谢杂志,2022,42(04):256.[doi:10.3760/cma.j.cn121383-20210420-04055]
Long Li,Zhang Xiuying,Ji Linong..New hope for the treatment of thyroid associated orbitopathy-IGF-Ⅰ receptor antagonist[J].International Journal of Endocrinology and Metabolism,2022,42(01):256.[doi:10.3760/cma.j.cn121383-20210420-04055]